Anixa Biosciences, Inc.

Company Snapshot: Anixa Biosciences, Inc.

Last Change Volume High Low

Company Overview

Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at

Client News

  1. Aug 15 2022 Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
  2. Jul 21 2022 Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
  3. Jun 21 2022 Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
  4. May 5 2022 Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference